Table 1.
Comprehensive overview of end point immunohistochemistry and longitudinal FDG-PET findings in treated and untreated hTau mice
| hTau Anle138b | hTau Vehicle | hTau pooled Baseline | Non-carrier controls (pooled) | |
|---|---|---|---|---|
|
Immunohistochemistry Frontal cortex (%-area) |
6.1 ± 1.9** | 12.9 ± 1.8 | 0 | |
|
Immunohistochemistry Frontal cortex (CP13+ neurons, N/mm2) |
1366 ± 116** | 2039 ± 153 | 0 | |
|
Immunohistochemistry Hippocampus (%-area) |
1.9 ± 1.4** | 4.8 ± 0.4 | 0 | |
|
Immunohistochemistry Hippocampus (CP13+ neurons, N/mm2) |
534 ± 18** | 619 ± 13 | 0 | |
|
FDG-PET baseline Frontal cortex (SUVR) |
0.97 ± 0.02 | 1.02 ± 0.09 | 1.00 ± 0.07# | 1.10 ± 0.10 |
|
FDG-PET follow-up Frontal cortex (SUVR) |
1.03 ± 0.05* | 0.95 ± 0.03# | 1.09 ± 0.06 | |
|
FDG-PET change Frontal cortex (ΔSUVR) |
+ 0.06 ± 0.06* | − 0.07 ± 0.09 | + 0.01 ± 0.05 | |
|
FDG-PET baseline Hippocampus (SUVR) |
0.93 ± 0.03 | 0.98 ± 0.10 | 0.96 ± 0.08# | 1.06 ± 0.10 |
|
FDG-PET follow-up Hippocampus (SUVR) |
1.00 ± 0.07 | 0.93 ± 0.05## | 1.05 ± 0.07 | |
|
FDG-PET change Hippocampus (ΔSUVR) |
+ 0.06 ± 0.05 | − 0.05 ± 0.10 | + 0.00 ± 0.05 |
Results summary: “*” indicates p < 0.05 and “**” indicates p < 0.005 in the direct comparison of hTau treatment and vehicle groups. “#” indicates p < 0.05 and “##” indicates p < 0.005 in the comparison of hTau groups (pooled baseline or treatment/vehicle during follow-up) versus non-carrier controls